Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437588 | 0.93 | HTT (0.62) | ATMHTTLMNAMEN1KMT2A | |
| SCHEMBL12437440 | 0.92 | TP53 (0.55) | ATMLMNATP53MAPTALDH1A1 | |
| SCHEMBL12513922 | 0.91 | ATM (0.52) | ATMHTTLMNATP53MEN1 | |
| SCHEMBL12437494 | 0.87 | ATM (0.50) | ATMLMNATP53MEN1KMT2A | |
| SCHEMBL12437589 | 0.85 | HTT (0.53) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL12437578 | 0.82 | MEN1 (0.55) | TP53MEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL12437496 | 0.82 | ATM (0.49) | ATMHTTLMNAMEN1KMT2A | |
| SCHEMBL12437585 | 0.82 | ALDH1A1 (0.47) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL12437514 | 0.81 | HRH3 (0.67) | LMNAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL12437516 | 0.79 | HRH3 (0.60) | LMNAMEN1KMT2AALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | ATM 4610/4885HTT 941/4885LMNA 2809/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | ATM 4610/4885HTT 941/4885LMNA 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.